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Background:Management using femoral-popliteal vein (FPV) of aortic graft infections, failing aortofemoral bypass, and
aortoiliac occlusive disease in young patients with a small aorta is now an accepted therapeutic method and is performed
frequently at our institution. A high reintervention rate for FPV graft stenosis has recently been reported. The purpose
of this study was to determine the incidence of FPV graft failure due to stenosis after neoaortoiliac system (NAIS)
reconstruction, and to identify risk factors for this complication.
Methods:A reviewwas performed of 240 patients who underwent NAIS reconstruction at our institution between January
1991 and December 2005. All patients were entered into a prospective database and were evaluated for the incidence of
vein graft stenosis requiring reintervention, risk factors for stenosis, and the rate and type of reintervention required to
assist patency. Patients with occlusion are evaluated and reported, but excluded from detailed analysis. Risk factors
assessed included gender, operative features, FPV size (diameter), smoking history, and medical comorbidities.
Results: Of the 240 NAIS procedures performed during this time period, 11 (4.6%) patients have required 12 graft
revisions (one patient required a second intervention) for stenosis using open and endovascular techniques. Over the same
time period, graft occlusion occurred in nine patients (3.8%). This provided a primary patency at 2 and 5 years of 87% and
82%, and an assisted primary patency rate of 96% and 94%. Mean time to revision was 23.5 months (range 5.5 to 83.5
months). Median FPV graft size in the nonrevised patients was 7.8 mm (range 4.0 to 11.4 mm), and 6.4 mm (range 4.7
to 8.7 mm) in the revised group (P  .006). Survival analysis revealed small vein graft size (<7.2 mm), coronary artery
disease (CAD), and extensive smoking history as independent predictors of time to stenosis (P  .002, .02, .01,
respectively), with multivariable analysis confirming these results (P  .002, .06, .012). Patients with CAD combined
with small graft size were found to be at especially high risk for stenosis, with 8/36 (22.2%) requiring revision vs 3/184
(1.6%) of patients without both factors (P < .0001).
Conclusions: FPV graft stenosis requiring revision after NAIS reconstruction is uncommon. Risk factors for stenosis
include small graft size, history of CAD, and smoking. All patients merit aggressive counseling for smoking cessation, and
patients exhibiting multiple risk factors should undergo close postoperative surveillance for graft stenosis. ( J Vasc Surg
2008;47:36-44.)The neoaortoiliac system reconstruction (NAIS) con-
sisting of in situ aortic reconstruction using femoral-
popliteal vein (FPV) has become an accepted method of
managing infected aortic grafts.1 This repair is associated
with lower rates of reinfection in comparison with in situ
synthetic graft and cryo-preserved allograft replacements,
and long-term patency is superior to extra-anatomic by-
pass.2,3 Additionally, NAIS is occasionally used at our
institution for failed aortofemoral bypass grafts as well as for
young patients with aortoiliac occlusive disease and small
aortic diameter. Previous reports from our institution have
demonstrated excellent durability of the NAIS operation,
with a primary patency rate at 5 years of 86%, and a
cumulative secondary patency rate of 100%.4
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36Faulk et al5 recently reported a graft stenosis rate of
23.5% after NAIS reconstruction in their small series of 17
patients. In our much larger experience, we have noted that
FPV graft stenosis occurs infrequently despite careful and
compulsive serial graft surveillance. We hypothesize that
(1) the incidence of FPV graft stenosis requiring reinter-
vention following NAIS reconstruction is low, and that (2)
there are specific risk factors for this long-term complica-
tion.
METHODS
Data collection. All patients undergoing NAIS recon-
struction at UT-Southwestern Medical Center and affili-
ated hospitals between January 1991 and December 2005
were entered prospectively into a database and their records
reviewed to identify those that required reintervention for
vein graft stenosis. Patients with and without vein graft
stenosis were compared for multiple variables including
age, gender, social habits (smoking history), medical co-
morbidities, and preoperative FPV diameter measure-
ments. Preoperative vein graft diameters were determined
with venous duplex ultrasonography, as previously de-
scribed.4
Operative procedure. The FPV was used for aortic
reconstruction in all patients. In most patients (91.3%), the
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ultrasonography before NAIS reconstruction to determine
patency and graft diameter. A small number of patients
(n 21/240; 8.7%) undergoing emergency NAIS did not
undergo preoperative venous duplex ultrasonography. All
venous duplex studies were reviewed, and the vein size was
determined by averaging diameters of both veins at three to
four sites along the length of the FPV. All venous duplex
studies were preformed with the head and trunk of the
patient elevated 20 to 30 degrees above the horizontal or
with the bed in a slight reverse Trendelenberg position.
Although there were bilateral measurements performed in
all patients with both lower extremities, it was impossible to
determine from operative data which vein graft (right or
left) was used for different segments of the NAIS recon-
struction.
The NAIS operation has been described in detail else-
where.6 Briefly, the FPV grafts were harvested from both
lower extremities. For infected grafts, the previous graft was
excised through an intraperitoneal or retroperitoneal ap-
proach, and all infected tissue was debrided from the retro-
peritoneum and femoral sites. In all procedures performed
prior to 2002, FPV valves were lysed using a Mills-Leather
valvulotome as previously described.4 An alteration in tech-
nique was instituted in 2002, when routine vein eversion
and direct valve excision became the standard method of
graft preparation.7 In order to provide the best possible size
match, veins were placed in a nonreversed fashion. Differ-
ing configurations of NAIS reconstruction were performed
according to patient anatomy, sites of infection, arterial
runoff, and vein graft length. Configurations have been
described in detail in previous reports,4,8,9 and all types of
reconstruction were included in this study.
Postoperative evaluation. Patients were followed
postoperatively at 4- to 6-month intervals with clinical and
noninvasive laboratory evaluation that included physical
examination, ankle-brachial indices (ABIs), toe pressures,
and duplex ultrasound of the FPV grafts. Criteria for the
presence of a hemodynamically significant stenosis included
a peak systolic velocity ratio equal to or greater than 3.0
(comparing the velocity at the site of stenosis with the
velocity immediately above or below that site), severely
disturbed flow at the site (color “mosaic” and spectral
broadening), and a 15% drop in the ABIs along with a
decrease in great toe pressures. Patients with stenosis were
evaluated further with computed tomographic or conven-
tional contrast angiography.
Our NAIS patient population represents a local, re-
gional, and national referral base, and patients are therefore
often followed elsewhere after discharge from our medical
center. Additionally, some of these patients come from the
indigent population in the Dallas-Fort Worth area and are
typically difficult to follow at routine intervals. Diligent
attempts were made to have patients followed at our insti-
tution whenever possible. Otherwise, patients were con-
tacted by phone and questioned regarding symptoms of
vascular insufficiency or a history of vascular intervention,
which might indicate graft failure. Specifically, patientswere queried regarding any outside vascular examinations
as well as claudication, rest pain, tissue or limb loss, and any
outside vascular interventions. In the patients successfully
contacted, no outside interventions were discovered. How-
ever, patients contacted by phone were censored in the data
analysis as lost to follow-up, as we cannot be certain of
whether they have developed stenosis or not.
If a patient was unable to be contacted, a search of the
Social Security Death Index (SSDI) was performed
(http://ssdi.rootsweb.com/) to determine if the patient
was deceased. At 2 years post-NAIS, which is themean time
to graft stenosis (23.5 months), 73% (n  125) of living
patients (n  171) were being followed within our institu-
tion. Another 16 (9%) of these patients were successfully
contacted by phone, were being followed at outside facili-
ties, and were without symptoms of graft failure.
Statistical analysis. Statistical analyses were per-
formed by statisticians in the Division of Biostatistics at the
Department of Clinical Sciences of The University of Tex-
as-Southwestern Medical Center. Primary patency was de-
fined as FPV grafts that were open at time of death, or at
completion of this study, without the need for reinterven-
tion. Assisted primary patency was defined as those grafts,
which were open at time of death or at study completion,
but required an additional intervention to treat graft steno-
sis. Kaplan-Meier analysis was used to assess primary pa-
tency, assisted primary patency, time to revision, and sur-
vival. Patients who required procedures to assist primary
patency were evaluated for risk factors predictive of graft
stenosis. Data from the patient that requiredmore than one
revision to assist primary patency was considered in the
statistical analysis only once.
The etiology of stenosis and occlusion are not neces-
sarily the same, therefore data analyses with and without
patients with occluded grafts were performed and reported.
However, detailed analyses of risk factors were performed
only on those patients with stenosis, specifically excluded
those who presented with occlusion.
Risk factors assessed by univariate and multivariable
survival analysis included gender, history of smoking, on-
going smoking after NAIS reconstruction, coronary artery
disease (CAD; defined below), hypertension (HTN; chart
history or documented BP  140/90 mm Hg), diabetes
mellitus (DM; chart history), chronic renal insufficiency
(CRI; defined by serum creatinine  1.8 mg/dL), end
stage renal disease (ESRD; defined as renal failure requiring
dialysis), chronic obstructive pulmonary disease (COPD;
chart history), and hyperlipidemia (HLIP; chart history). A
history of CAD was defined as patients with a history of
coronary revascularization, pre-existing history of angina
pectoris, myocardial infarction, ischemic cardiomyopathy,
or previously documented disease by invasive or noninva-
sive cardiac evaluation.
Excluding the occlusion patients, the association be-
tween covariates and the time to revision was evaluated by
log rank test (for categorical variables) and a Cox propor-
tional hazard model (for continuous variables). In the
categorical analysis, the outcome is binary (revised or not),
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the continuous and binary covariates. For the survival anal-
ysis, the outcome is time to revision (censored by the
follow-up time), and a Cox proportional hazard model and
log rank tests were used for the continuous and binary
covariates. The Kaplan-Meier method was used to fit the
revision-free survival curves. To ascertain differences be-
tween groups, the continuous variables (graft size and pack
year history) were dichotomized into two groups and the
cutoff values were chosen based on a univariate survival
tree.10
To separate patients at high risk of revision due to
stenosis from those with low risk, we used the CART
(classification and regression tree),11 which is a tree-based
method based on univariate survival data that recursively
splits patients into groups with similar prognoses. Specifi-
cally, in this study, the survival tree was built with the
outcome being time to revision censored by the follow-up
time.12,13 Covariates (graft size, pack year history, and
CAD) that were found to be associated with time to revi-
sion in a survival analysis were used as input into the survival
tree analysis. The threshold for node splitting was chosen to
be 0.01 (for each node split, the significant level was
assessed by a log-rank test, and the tree kept splitting until
there were no separations with a P value less than .01).
RESULTS
Over a 15-year period at our institution, 240 patients
underwent NAIS reconstruction. Patient demographics are
shown in Table I. NAIS reconstruction was performed for
one of three indications, infection (n 181; 75.4%), aorto-
femoral bypass (AFB) failure (n 18; 7.5%), and aorto-iliac
occlusive disease with a small aorta (n  41; 17.1%). The
primary procedure before NAIS in the infection group was
Table I. Patient demographics
Nonrevised
(n  220)
R
(n
Demographics
Median age 60 5
Male 60.9 3
Female 39.1 6
Median vein graft diameter (mm) 7.65
Comorbidities
Coronary artery disease 44.1 7
Hypertension 82.3 10
COPD 14.9 1
Hyperlipidemia 40.0 4
Chronic renal insufficiency 7.3
End stage renal disease 2.7
Diabetes mellitus 21.4 2
Social habits
History of smoking 95.9 10
Mean pack-year-history 40 6
Ongoing smoking after NAIS 46.5 7
COPD, Chronic obstructive pulmonary disease; NAIS, neoaortoiliac systemocclusive in 154 (85%), aneurysmal in 9 (5%), and both in18 (10%). Of these 240 patients, 20 patients developed
stenosis (n  11, 4.6%) or occlusion (n  9, 3.8%) provid-
ing a primary patency at 2 and 5 years of 87% and 82%,
respectively, and an assisted primary patency rate at 2 and 5
years of 96% and 94% by Kaplan-Meier analysis (Fig 1, A).
Eleven patients required 12 interventions for stenosis. Nine
of these patients underwent NAIS for infected aortic grafts,
and one patient each had the procedure for a failed AFB and
aortoiliac disease in a young patient with a small aorta
(termed “primary NAIS”). There was no statistical differ-
ence in rate of stenosis between different indications for the
NAIS procedure (infection vs AFB failure vs primary
NAIS), configuration of NAIS, or initial indication for the
primary procedure (occlusive disease vs aneurysmal).
Eight patients (73%) were noted to be symptomatic
from their stenosis at the time of diagnosis. Also, the patient
who underwent two separate graft revisions was symptom-
atic before both revisions, thus, nine of 12 interventions
were performed for symptomatic disease (75%). Demo-
graphics in this group are demonstrated in Table II.
Mean time from NAIS reconstruction to the first inter-
vention for stenosis was 23.5 months (range 5.5 to 83.5
months), with a patient survival at 2 years of 71.4% (Fig 1,
B). Interventions were performed using endovascular tech-
niques in 5/12 (42%), and open in 7/12 (58%). Technical
success was achieved in all patients undergoing open and
endovascular interventions. Of the five patients undergoing
percutaneous interventions for their vein graft stenosis, two
had two separate stenotic lesions in their FPV grafts. Both
of those patients required balloon angioplasty (PTA) of one
lesion and PTA with subsequent placement of a stent of the
other lesion. Two patients each had a single lesion that was
treated with PTA and stent. One female patient, who was
17 months out from NAIS reconstruction underwent PTA
)
P value
Categorical
analysis
Survival
analysis Relative risk (95% CI)
.57 .59 0.99 (0.93, 1.05)
.12 .12
.006 .002 0.54 (0.37, 0.87)
.12 .02 4.23 (1.12 to 16.0)
.22 .16
.66 .36
.76 .83
.99 .47
.99 .85
.71 .74
.99 .42
.08 .01 1.26 (1.02, 1.54)
.12 .19evised
 11
8
6.4
3.6
6.35
2.7
0
8.2
5.5
0
0
7.3
0
0
2.7of a proximal limb stenosis which resulted in graft rupture
ision.
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fully managed with a covered stent and required no further
intervention.
Seven patients were treated with open revision of their
NAIS grafts, one of which was a second intervention. One
patient required vein patch angioplasty of both FPV seg-
ments. Four patients were managed with open vein patch
angioplasty of a single stenotic lesion. Another patient
underwent femoral-femoral crossover bypass with great
saphenous vein for bypass of a unilateral NAIS graft limb
stenosis.
The patient requiring a second intervention first under-
went bilateral angioplasty and stent placement performed
for bilateral mid-graft stenoses at 13.5 months, with a
second intervention at 32.5 months for a separated stenosis
at the aorto-FPV anastamosis (Fig 3). This stenosis was
Fig 1. A, Kaplan-Meier curves demonstrating primary
neoaortoiliac system (NAIS) procedure. B, Patient surv
assisted primary patency as well as survival.
Table II. Revised patient demographics
Age Gender Time (mo) interval Graft dia. (mm)
66 F 13.5 4.6
* 32.5
60 F 33.0 5.1
87 F 5.0 5.4
65 M 6.0 5.8
64 F 20.0 6.0
55 F 11.0 6.4
54 F 17.0 6.8
55 M 15.5 7.0
58 F 32.5 7.1
42 M 12.5 8.3
50 M 83.5 8.7
PTA, Percutaneous transluminal angioplasty; B, bilateral; R, right; L, left; G
*Denotes patient requiring second revision and specifics regarding that revmanaged with a Dacron patch angioplasty as there was noavailable vein for the repair. Additionally, this patient re-
quired a repair of the contralateral limb during the second
intervention due to an injury incurred during exposure of
the NAIS graft.
Although there have been fewer vein graft stenoses
(three patients) since 2002, when the change in technique
from valve lysis to direct valve excision occurred, the overall
difference in the rate of stenosis during the time periods
before and after 2002 was not significantly different
(P  .23).
Risk factors for stenosis. Using a univariate analysis,
CAD was the only medical comorbidity significantly
associated with graft stenosis. Patients with CAD were
significantly more likely to have stenosis, with a relative
risk (RR) of 4.23. (Cox proportional hazard model, P 
.02; RR 4.23, 95% confidence interval [CI] 1.12 to 16.0)
assisted-primary patency up to 100 months after the
fter NAIS. The tabular life table refers to primary and
Stenosis site Intervention method
B limbs PTA/stent R; PTA L
Aortic Dacron patch angioplasty
R limb/aortic Aortic limb PTA/stent; R limb PTA
L Limb Femoral-femoral bypass
Femoral-femoral limb GSV patch angioplasty
L limb GSV patch angioplasty
L limb GSV patch angioplasty
R limb PTA, rupture, covered stent
Femoral-femoral limb GSV patch angioplasty
L limb PTA/stent
B limbs GSV patch angioplasty B limbs
Femoral-femoral limb PTA/stent
reat saphenous vein; mo, months; Dia, diameter; mm, millimeters.and
ival aSV, g(Table I). Multivariable analysis showed a trend toward
furth
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(P  .06).
Median FPV graft diameter in patients who developed
stenosis was 6.4 mm (range 4.7 mm to 8.7 mm) and 7.8
mm (range 4.0 mm to 11.4 mm) in those with no stenosis
(P .006, Wilcoxon rank sum test). FPV size was found to
be an independent predictor of stenosis (Table I) and
patients with smaller FPV size are more likely to have
stenosis. Additionally, of the patients undergoing revision,
those with larger graft size had a significantly longer time to
revision (P  .002, Cox proportional hazard model) (Fig
4). More specifically, if the graft size of a patient were
increased by 1 millimeter, the relative risk of needing
revision would be halved (RR 0.44 with 95% confidence
interval from 0.27 to 0.73, Cox proportional hazard
model). There was no significant differences in the age or
gender of patients requiring revision (Table I), although
the incidence of stenosis in females (7/98; 7.1%) was
higher than in males (4/142; 2.8%) P  .12. Graft diame-
Fig 2. Angiogram images demonstrate a right proximal
diagnosed 17months after the original reconstruction. Ba
balloon inflated to 16 atmospheres of pressure with resul
managed with covered stent placement and required no
Fig 3. This patient required two separate interventions
unrelated locations in the grafts. The left image demons
stent at 13.5 months after NAIS. At 32.5 months after
stenosis at the aorto-FPV limb (Right; arrow).ter of female patients (mean 6.9) was significantly smallerthan that of male patients (mean 8.1) (P  .0001), but
gender was not found to be a confounder for association
between graft size and time to revision.
Heavy smoking was also an independent risk factor for
time to stenosis (P  .01) (Table I). An increase in 10
pack-years of smoking cigarettes was associated with a 27%
increase in relative risk of stenosis (RR 1.27, 95% CI 1.06 to
1.52).
When occlusion patients are included in the data
analysis, these data are similar. By multivariable survival
analysis, vein graft diameter and CAD were related to
stenosis/occlusion (P  .004 and .01, respectively).
However, pack-year-history (PYH) of smoking showed
only a trend toward significance at P  .09.
Stenosis prediction model. To further classify pa-
tients at high risk for stenosis and need for revision, a
survival tree was created with graft size, smoking PYH, and
CAD, exclusive of patients with graft occlusion. The tree is
demonstrated in Fig 5. Patients with graft size less than 7.2
ortoiliac system (NAIS) limb stenosis (left image; arrow)
angioplasty (center image) was performedwith an 8mm
raft rupture (right image; arrow). This complication was
er intervention.
eoaortoiliac system (NAIS) limb stenoses occurring at
the first stenosis and its management with angioplasty/
, the same patient required a second intervention for aneoa
lloon
ting gfor n
trates
NAISmm and a concomitant history of CAD were identified as
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low risk (RR 0.37). Further, eight out of 36 (22.2%) of
patients in the high-risk group had revision while only three
out of 184 (1.6%) (P  .0001) of patients in the low risk
group required revision.
DISCUSSION
Aortic graft infection presents a difficult clinical prob-
lem in a high-risk patient population. Therefore, surgical
correction of this problem should be durable and offer the
lowest possible risk. NAIS also provides an excellent alter-
native method of management in patients with AFB failure,
or those patients with early aorto-iliac occlusive disease in
the setting of a small aortic diameter. In comparison with
other available methods of treatment, NAIS reconstruction
with FPV provides a resilient, relatively low-risk procedure,
with a low reintervention rate.
This analysis focused specifically on patients with graft
stenosis, excluding those who presented with occlusion.
Graft stenosis due to intimal hyperplasia or atheromatous
plaque formation is a progressive process, the most feared
complication of which is eventual occlusion. However, the
etiology of graft occlusion is often multifactorial and can
also include technical error, hypercoagulable states, throm-
boembolic phenomena, or issues with arterial in-flow/out-
flow. None of the patients that presented with occlusion
were previously noted on routine follow-up to have a
stenotic lesion in their vein grafts, nor did they have symp-
toms concerning for impending graft failure. Because of the
uncertainty of whether stenosis preceded occlusion in this
patient population, an analysis was performed both with
and without patients that experienced graft occlusion. In
Fig 4. Kaplan-Meier curves demonstrating primary patency of
vein grafts7.2 mm (upper line) and small vein grafts (lower line).
Small preoperative vein graft diameter (7.2 mm) was found to be
an independent risk factor for stenosis (P  .006) in a survival
analysis.order to specifically determine risk factors for stenosis, adetailed analysis of risk factors was focused on patients with
stenosis only, exclusive of those patients who presented
with graft occlusion. Unfortunately, eliminating these pa-
tients from the data analysis likely excludes some patients
who had asymptomatic stenosis progressing to occlusion.
In our early experience, open revision was the preferred
method of management of stenotic lesions simply because of
comfort level with that modality. In more recent years, endo-
vascular management has become our preferred method of
management, unless there are anatomic limitations (ie, the
stenosis is immediately at the anastomosis), which has been
uniformly technically successful. However, one complication
was incurred during treatment of stenosis. Angioplasty of a
NAIS limb thatwas 17months postoperativewas complicated
by partial disruption of the FPV graft. The hyperplastic etiol-
ogy of these lesions necessitates aggressive angioplasty with
high balloon pressures for dilation. This graft ruptured at 16
atm of pressure and was recognized immediately (Fig 2).
Although this patient did well and had no further problems
after covered stent placement, we recommend caution when
performing angioplasty in these grafts.
On occasion, stenotic NAIS graft samples have been
taken intraoperatively and examined histologically. All of
these have demonstrated intimal hyperplasia at the site of
stenosis, rather than complex atheromatous plaque forma-
tion (unpublished data). This is not unexpected, and is
consistent with the relatively early occurrence of stenosis in
these patients.14
Heavy smoking history, relatively small FPV graft, and
CAD were all found to be independent predictors of vein
graft stenosis. The only modifiable risk factor identified for
stenosis was smoking. Smoking is known to be a risk factor
for both the occurrence of peripheral arterial disease
(PAD), as well as progression of disease.15 Epidemiological
studies have shown smokers to have a 1.7- to 5.6-fold
higher risk of developing PAD than do nonsmokers,16 and
PAD is usually diagnosed up to 10 years earlier in smokers.
Aortofemoral bypass graft failure has been shown to be
more common in heavy smokers,17 and smoking cessation
is the most important determinant of outcome in patients
with PAD, so it is not surprising that extensive smoking
history would impart risk for stenosis in the NAIS patient
population. Inclusion of patients with occlusion in the
analysis led to a nonsignificant P value (P .09) regarding
smoking and graft complication. We believe that this may
be due to the difference in etiology mentioned previously
and is likely skewed data since one patient in the occlusion
group had no history of smoking, obviating smoking as a
cause of graft complication in that patient.
We also found that relatively small diameter FPV grafts
were prone to develop stenosis. This is expected since small
saphenous vein graft size is known to be a risk factor for
graft stenosis after peripheral arterial bypass.18,19 In our
early experience, we abandoned saphenous vein grafts for
NAIS reconstructions because of the high incidence of
graft stenosis leading to occlusion.4 We attributed the high
rate of stenosis to the small caliber of saphenous vein grafts
in comparison with larger diameter FPV grafts that had a
risk patients (those with one or neither risk factor).
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occlusion.4Here we have demonstrated that FPV grafts less
than 7.2 mm had a significantly higher risk of stenosis. This
is a size threshold, based on the computer-generated statis-
tical (survival tree) analysis, which separates vein grafts
according to their propensity to develop stenosis. In point
of fact, the majority of FPV grafts at or below this threshold
functioned well and did not develop stenosis. Therefore,
we continue to use FPV grafts less than 7 mm in diameter
but recommend close postoperative surveillance of these
patients with duplex ultrasonography. In the unusual situ-
ation of vein grafts smaller than 5 mm in diameter, we seek
alternative revascularization options.
A history of CAD was also found to be a significant risk
factor for stenosis in our patient population. This probably
reflects a systemic predisposition for the development of
atherosclerosis and its complications in these patients. This
finding underscores the importance of risk factor modifica-
tion in the long-term care of these patients and identifies a
subgroup that may need closer graft surveillance.
All stenoses requiring revision were noted to involve a
short segment of vein, perhaps consistent with a valve site
(Fig 6), but this cannot be confirmed. Due to our concern
regarding possible incomplete valve lysis leading to steno-
sis, our technique of valve lysis was changed in 2002 from
the use of a valvulotome to complete vein eversion and
direct valve excision. Since that time, three patients have
required revision for vein graft stenosis. Although we were
unable to demonstrate a significant reduction in stenosis
Fig 5. (Left) Classification and regression tree used to de
oval denotes a high risk group having both small grafts an
right is a Kaplan-Meier analysis demonstrating revision
patients (those with both CAD and small grafts) vs low-rate since adopting the technique of eversion and directFig 6. All stenoses were noted to involve a short segment of the
neoaortoiliac system (NAIS) limb. This image demonstrates a
preoperative three dimensional computed tomographic image of a
short-segment NAIS stenosis (arrow) noted at 11 months after the
original reconstruction. This was managed with an open saphe-termine patients at high risk for stenosis. The bottom left grey
d a personal history of coronary artery disease (CAD). On the
-free survival after neoaortoiliac system (NAIS) in high-risknous vein patch angioplasty.
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error. We continue to practice and recommend valve exci-
sion if FPV grafts are placed in a nonreversed position.
Our current practice is to monitor high risk patients
(particularly those with vein grafts 7 mm), as defined by
this study, with duplex ultrasound every 4 months for the
first 2 years after NAIS, and every 6 months after that. All
other patients are monitored with every 6-month ultra-
sound for the first year and yearly thereafter.
There are limitations to this study. We are unable to
definitively demonstratewhether a pre-existing small diameter
segment of vein led to graft failure, or if stenosis is due to a
generally small graft. Which vein (right or left) was used for
eachNAIS limbwas not documented, and for the purposes of
this study, an average of several diameter measurements along
the vein grafts was used for the statistical analysis. It is conceiv-
able that a small graft with a narrow segment may be at even
higher risk than a uniformly small graft.
Additionally, our definition of patients with history of
CAD is likely not all-inclusive, as it is known that the
majority of patients (approaching 100%) in this patient
population have atherosclerosis in multiple vascular beds,
and some degree of coronary disease. However, we have
focused on those patients with clinically significant disease
in an attempt to include patients with more advanced or
aggressive atherosclerotic disease.
Furthermore, our data may underestimate the number of
stenoses that develop, or could develop, in our patient popu-
lation. Nearly one-third (29.6%) of patients did not live to 24
months, the mean time to stenosis recognition. Based on the
known fate of many PAD patients, a large proportion of these
patients likely died a cardiac death (although this was not
confirmed) and, based on these data presented here, these
patients may have been at high risk for graft stenosis had they
survived longer. As noted previously, other patients have
either been lost to follow-up entirely by 2 years after their
NAISor havebeen followed at distant, outside facilities (27%).
Despite these limitations, we believe that a sufficient number
of patients have been followed for an adequate period of time
to demonstrate the durability of theNAIS procedure aswell as
the potential for developing vein graft stenosis.
We greatly appreciate the statistical expertise and assis-
tance of Guanghua (Andy) Xiao, PhDwith theDepartment
of Clinical Sciences at The University of Texas-Southwest-
ern Medical Center.
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Dr Gregory Pearl (Dallas, Tex). In your initial diagram you
showed a nice configuration of two superficial femoral veins with
an anastomosis between those two segments. Did you have any
patients that required more than two segments sewn together? Did
that impact your outcomes at all?
DrAdamW. Beck (Dallas, Tex). Yes, I believe so. There were
a few patients that had to have patched together vein grafts, but
none of those patients have developed stenoses.
Dr John Ricotta (Stony Brook, NY). I have three questions
for you.
First, could you tell us what the sites of recurrence were? Were
they at anastomotic sites, sites of vein valves?
Second, in your last slides it seemed to me that if you did not
have coronary disease, you still did quite well even with a small
vein. And given that, what are your feelings about vein size?
And last, in your definition of smoking, was that any history of
smoking or was it persistent smoking after the procedure was done?Dr Beck. I will answer your last question first. The smoking
was nearly 100% prevalent in this population. We did look at
persistent smoking after the NAIS, and it was not statistically
significant. The P value of stenosis in persistent smokers was 0.12
versus patients that quit smoking after NAIS. The relative risk
increase for every 10 pack year history of smoking is 0.27, so there
is a 27% increase in relative risk.
Regarding where the lesions were in the NAIS graft, they were
distributed everywhere. We had one that was immediately at an
anastomotic site. Most of them were either close to the anastomo-
sis or in the mid graft.
I think you bring up a very good point that even though we
dichotomized the patients into above or below 7.2 mm, in point of
fact, there are a large number of patients that had grafts less than
7.2 mm in diameter who have done fine and have not had any
stenoses to date. Because of this, we do not use size less than 7 mm
as a contraindication for this procedure.
